EMEA-003058-PIP01-21
Key facts
| Active substance |
Humanised KLB/FGFR1c monoclonal antibody (MK-3655)
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/0186/2022
|
| PIP number |
EMEA-003058-PIP01-21
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of non-alcoholic steatohepatitis (NASH)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Merck Sharp & Dohme (Europe), Inc.
Email: pip.information@merck.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|